Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFTERS: Contrast-Enhanced Ultrasound for Evaluating Renal Scarring
NCT03653702Phase 1Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Jul 2027
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulfur hexafluoride lipid type a microspheres in vesicoureteral reflux (VUR) and renal scarring, sponsored by Boston Children's Hospital. Primary endpoint: Performance of CEUS result and comparison to DMSA at 3 months. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
sulfur hexafluoride lipid type a microspheres
03
Conditions
vesicoureteral reflux (VUR)renal scarring
Beyond the preview
Go deeper on NCT03653702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653702.